Literature DB >> 6365790

Antibacterial activity and kill kinetics of amoxicillin-clavulanic acid combinations against Escherichia coli and Klebsiella aerogenes.

J E Fuglesang, T Bergan.   

Abstract

Combinations of amoxicillin and clavulanic acid were tested against 11 Escherichia coli strains and five Klebsiella aerogenes strains. Apart from one E. coli, the strains were highly resistant to amoxicillin due to beta-lactamase production. Synergy was demonstrated in all strains by agar dilution. Synergy was detected against the beta-lactamase-producing strains under simulated in vivo conditions with constantly decreasing concentrations simulating in vivo pharmacokinetics. The correlation between antibacterial activity determined by minimum inhibitory concentrations and bacterial kill kinetics in the in vivo simulation model was acceptable. A higher bacterial kill rate was observed when the antibiotic dosage was increased beyond the minimum concentration where an antibacterial effect was seen; this was not demonstrable by traditional agar dilution tests. In combination, a greater relative amount of amoxicillin compared to clavulanic acid allows a reduction in the total amount of antimicrobial agents with the same degree of antibacterial activity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6365790     DOI: 10.1007/bf01641359

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  22 in total

1.  Clavulanic acid: a beta-lactamase-inhiting beta-lactam from Streptomyces clavuligerus.

Authors:  C Reading; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

2.  The interplay of beta-lactamases and intrinsic factors in the resistance of gram-negative bacteria to penicillins and cephalosporins.

Authors:  M H Richmond; N A Curtis
Journal:  Ann N Y Acad Sci       Date:  1974-05-10       Impact factor: 5.691

3.  Therapy with combinations of penicillin analogues in urinary-tract infections.

Authors:  L Riff; V M Olexy; G G Jackson
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

Review 4.  The beta-lactamases of gram-negative bacteria and their role in resistance to beta-lactam antibiotics.

Authors:  R B Sykes; M Matthew
Journal:  J Antimicrob Chemother       Date:  1976-06       Impact factor: 5.790

5.  Augmentin (amoxycillin and clavulanic acid) therapy in complicated infections due to beta-lactamase producing bacteria.

Authors:  D A Leigh; K Bradnock; J M Marriner
Journal:  J Antimicrob Chemother       Date:  1981-03       Impact factor: 5.790

6.  In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin.

Authors:  P A Hunter; K Coleman; J Fisher; D Taylor
Journal:  J Antimicrob Chemother       Date:  1980-07       Impact factor: 5.790

7.  Antibacterial kinetics of ampicillin against Escherichia coli under simulated in vivo conditions.

Authors:  J E Fuglesang; T Bergan
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

8.  Factors contributing to resistance to beta-lactam antibiotics in Bacteroides fragilis.

Authors:  B Olsson; K Dornbusch; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

9.  Comparative activity of BRL 25.000 with amoxycillin against resistant clinical isolates.

Authors:  H W Van Landuyt; M Pyckavet; A M Lambert
Journal:  J Antimicrob Chemother       Date:  1981-01       Impact factor: 5.790

10.  Inhibitory activity and bactericidal kinetics of mecillinam/ampicillin combinations against Enterobacteriaceae, Pseudomonas and Acinetobacter.

Authors:  J E Fuglesang; T Bergan; T Bielecki; A Naterstad; E Namork
Journal:  Infection       Date:  1981       Impact factor: 3.553

View more
  1 in total

1.  Antibacterial activity and kill kinetics of ampicillin/sulbactam (CP-45899) combinations against Escherichia coli and Klebsiella aerogenes.

Authors:  J E Fuglesang; T Bergan
Journal:  Infection       Date:  1984 Jan-Feb       Impact factor: 3.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.